These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 2867823)

  • 21. Use of somatostatin and somatostatin analogs in a patient with a glucagonoma.
    Kahn CR; Bhathena SJ; Recant L; Rivier J
    J Clin Endocrinol Metab; 1981 Sep; 53(3):543-9. PubMed ID: 6114963
    [No Abstract]   [Full Text] [Related]  

  • 22. [Necrolytic migratory erythema as the first manifestation of glucagonoma].
    Chang CH; Sheu HM; Cheng GS; Yu HS
    J Formos Med Assoc; 1991 Dec; 90(12):1240-5. PubMed ID: 1686896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [A human pancreatic glucagonoma, ultrastructural, immunocytochemical and radioimmunological investigations (author's transl)].
    Voigt JJ; Hollande E; Pradayrol L; Vinel JP; Gorguet B
    Ann Pathol; 1981; 1(4):287-97. PubMed ID: 6274365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagonoma syndrome.
    Bloom SR; Polak JM
    Am J Med; 1987 May; 82(5B):25-36. PubMed ID: 2884877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful treatment of glucagonoma-related necrolytic migratory erythema with dacarbazine.
    van der Loos TL; Lambrecht ER; Lambers JC
    J Am Acad Dermatol; 1987 Feb; 16(2 Pt 2):468-72. PubMed ID: 3029193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Glucagonoma with diabetic ketoacidosis; case report].
    Lefebvre J; Lelièvre G; Dalle-Furnari MA; Proye C; Mazzuca M; Garraud JC; Luyckx A; Linquette M
    Diabete Metab; 1982 Sep; 8(3):191-5. PubMed ID: 6292011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature.
    Rosenbaum A; Flourie B; Chagnon S; Blery M; Modigliani R
    Digestion; 1989; 42(2):116-20. PubMed ID: 2548911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The glucagonoma syndrome in a Chinese man.
    Lee KO; Chan HL; Lee HL
    Ann Acad Med Singap; 1985 Apr; 14(2):312-6. PubMed ID: 2994543
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment of necrolytic migratory erythema in glucagonoma syndrome.
    Shepherd ME; Raimer SS; Tyring SK; Smith EB
    J Am Acad Dermatol; 1991 Nov; 25(5 Pt 2):925-8. PubMed ID: 1761771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of somatostatin on skin lesions and concentrations of plasma amino acids in a patient with glucagonoma-syndrome.
    Schmid R; Allescher HD; Schepp W; Hölscher A; Siewert R; Schusdziarra V; Classen M
    Hepatogastroenterology; 1988 Feb; 35(1):34-7. PubMed ID: 2896149
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A case with glucagonoma syndrome--heterogeneity of glucagon and insulin.
    Fukushima H; Yamaguchi K; Uzawa H
    Endocrinol Jpn; 1981 Oct; 28(5):575-82. PubMed ID: 6284494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Distribution of plasma glucagon immunoreactivity in a patient with suspected glucagonoma.
    Valverde I; Lemon HM; Kessinger A; Unger RH
    J Clin Endocrinol Metab; 1976 May; 42(5):804-8. PubMed ID: 178682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Unsuccessful DTIC treatment of a patient with glucagonoma syndrome.
    Hallengren B; Dymling JF; Manhem P; Tennvall L; Tibblin S
    Acta Med Scand; 1983; 213(4):317-8. PubMed ID: 6310975
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Excessive circulating large molecular weight immunoreactive glucagon components in subjects with the idiopathic postprandial syndrome.
    Charles MA; Waldeck N
    J Clin Endocrinol Metab; 1981 Aug; 53(2):366-71. PubMed ID: 6265488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heterogeneity of plasma glucagon. Circulating components in normal subjects and patients with chronic renal failure.
    Kuku SF; Jaspan JB; Emmanouel DS; Zeidler A; Katz AI; Rubenstein AH
    J Clin Invest; 1976 Sep; 58(3):742-50. PubMed ID: 956399
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Necrolytic migratory erythema revealing glucagonoma without diabetes].
    Marty C; Bennet A; Bayle P; Danjoux M; Lalande T; Marguery MC; Bazex J
    Ann Med Interne (Paris); 2003 Dec; 154(8):552-6. PubMed ID: 15037834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagonoma without cutaneous manifestations.
    Parr JH; Ramsay ID; Keeling PW; Thompson RP; Mallinson CN
    Postgrad Med J; 1985 Aug; 61(718):737-8. PubMed ID: 2994032
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disappearance of glucagonoma rash after surgical resection, but not during dietary normalization of serum amino acids.
    Abraira C; DeBartolo M; Katzen R; Lawrence AM
    Am J Clin Nutr; 1984 Mar; 39(3):351-5. PubMed ID: 6320631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Plasma glucagon levels suppressed by a glucose load in a man with incidental pancreatic glucagonoma.
    Mai VQ; Jones RC; Dickert JM; Clyde PW; Shakir KM
    Endocr Pract; 2007; 13(7):780-4. PubMed ID: 18194937
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plasma immunoreactive glucagon fractions in four cases of glucagonoma: increased "large glucagon-immunoreactivity".
    Recant L; Perrino PV; Bhathena SJ; Danforth DN; Lavine RL
    Diabetologia; 1976 Aug; 12(4):319-26. PubMed ID: 183997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.